101 related articles for article (PubMed ID: 12596264)
1. Local protein unfolding and pathogenesis of polyglutamine-expansion diseases.
Chen YW
Proteins; 2003 Apr; 51(1):68-73. PubMed ID: 12596264
[TBL] [Abstract][Full Text] [Related]
2. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease.
Chow MK; Paulson HL; Bottomley SP
J Mol Biol; 2004 Jan; 335(1):333-41. PubMed ID: 14659761
[TBL] [Abstract][Full Text] [Related]
3. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
4. Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease.
Chow MK; Ellisdon AM; Cabrita LD; Bottomley SP
J Biol Chem; 2004 Nov; 279(46):47643-51. PubMed ID: 15345714
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
Ghosh S; Feany MB
Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
[TBL] [Abstract][Full Text] [Related]
6. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils.
Bevivino AE; Loll PJ
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):11955-60. PubMed ID: 11572942
[TBL] [Abstract][Full Text] [Related]
7. Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis.
Ricchelli F; Fusi P; Tortora P; Valtorta M; Riva M; Tognon G; Chieregato K; Bolognin S; Zatta P
Int J Biochem Cell Biol; 2007; 39(5):966-77. PubMed ID: 17300980
[TBL] [Abstract][Full Text] [Related]
8. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract.
Wellington CL; Ellerby LM; Hackam AS; Margolis RL; Trifiro MA; Singaraja R; McCutcheon K; Salvesen GS; Propp SS; Bromm M; Rowland KJ; Zhang T; Rasper D; Roy S; Thornberry N; Pinsky L; Kakizuka A; Ross CA; Nicholson DW; Bredesen DE; Hayden MR
J Biol Chem; 1998 Apr; 273(15):9158-67. PubMed ID: 9535906
[TBL] [Abstract][Full Text] [Related]
9. Hosting neurotoxicity in polyglutamine disease.
Liu N; Bonini NM
Cell; 2006 Dec; 127(7):1299-300. PubMed ID: 17190592
[TBL] [Abstract][Full Text] [Related]
10. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional analysis of the Josephin domain of the polyglutamine protein ataxin-3.
Chow MK; Mackay JP; Whisstock JC; Scanlon MJ; Bottomley SP
Biochem Biophys Res Commun; 2004 Sep; 322(2):387-94. PubMed ID: 15325242
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
[TBL] [Abstract][Full Text] [Related]
13. Canadian Association of Neurosciences Review: polyglutamine expansion neurodegenerative diseases.
Truant R; Raymond LA; Xia J; Pinchev D; Burtnik A; Atwal RS
Can J Neurol Sci; 2006 Aug; 33(3):278-91. PubMed ID: 17001815
[TBL] [Abstract][Full Text] [Related]
14. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70.
Warrick JM; Chan HY; Gray-Board GL; Chai Y; Paulson HL; Bonini NM
Nat Genet; 1999 Dec; 23(4):425-8. PubMed ID: 10581028
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
16. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA pathways modulate polyglutamine-induced neurodegeneration.
Bilen J; Liu N; Burnett BG; Pittman RN; Bonini NM
Mol Cell; 2006 Oct; 24(1):157-63. PubMed ID: 17018300
[TBL] [Abstract][Full Text] [Related]
18. Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila.
Kretzschmar D; Tschäpe J; Bettencourt Da Cruz A; Asan E; Poeck B; Strauss R; Pflugfelder GO
Glia; 2005 Jan; 49(1):59-72. PubMed ID: 15390099
[TBL] [Abstract][Full Text] [Related]
19. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
20. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
Bauer PO; Nukina N
J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
